Hemab Therapeutics (NASDAQ:COAG) Shares Gap Up – Still a Buy?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) shares gapped up prior to trading on Tuesday. The stock had previously closed at $30.07, but opened at $32.16. Hemab Therapeutics shares last traded at $33.03, with a volume of 11,407 shares traded.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. HC Wainwright boosted their target price on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Weiss Ratings downgraded Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, September 25th. Jefferies Financial Group raised their price target on Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Rodman & Renshaw initiated coverage on Hemab Therapeutics in a research note on Monday, October 12th. They issued a “buy” rating and a $56.00 price objective on the stock. Finally, Wedbush boosted their price objective on Hemab Therapeutics from $55.00 to $64.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $54.71.

Hemab Therapeutics Stock Performance

The stock’s fifty day simple moving average is $39.81.

Hemab Therapeutics (NASDAQ:COAG) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.17). As a group, equities analysts anticipate that Hemab Therapeutics Holdings, Inc. will post -3.10 EPS for the current year.

Institutional Investors Weigh In On Hemab Therapeutics

A number of institutional investors have recently added to or reduced their stakes in COAG. Squarepoint Ops LLC bought a new position in Hemab Therapeutics during the second quarter valued at about $230,000. The Manufacturers Life Insurance Company bought a new stake in shares of Hemab Therapeutics in the 2nd quarter worth approximately $688,000. Opaleye Management Inc. bought a new stake in shares of Hemab Therapeutics in the 2nd quarter worth approximately $1,750,000. State Street Corp acquired a new stake in shares of Hemab Therapeutics during the 2nd quarter worth approximately $2,825,000. Finally, Braidwell LP acquired a new stake in shares of Hemab Therapeutics during the 2nd quarter worth approximately $5,877,000.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious bleeding disorders. The company’s research is aimed at addressing conditions in which patients experience inadequate clot formation or difficulty controlling bleeding, including rare inherited and acquired disorders.

Hemab’s lead investigational program, HMB-001, is being developed as a potential treatment for Glanzmann thrombasthenia, a rare inherited platelet disorder that can cause severe and recurring bleeding.